Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2025-05-13 00:00:00 ET · period of report 2025-05-12 · accession 0001104659-25-047938 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-05-13 | 2025-05-12 | NVCT | Mosseri Marlio Charles | 10% | P - Purchase | $8.11 | +21.2K | 2.94M | +0.7% | +$171.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-12 | P | A | 21,167 | $8.11 | 2,942,761 | I By Emerald Hill Ventures SARL SPF. | — | — | (F1) Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.11 to $8.12. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. (F2) Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL. |